New study tests if MRI-Guided biopsy spots aggressive prostate cancer better than standard method

NCT ID NCT03234556

Ongoing Diagnosis Sponsor: University of Southern California Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinically significant prostate cancer (Gleason score 7 or higher). The study involves 288 participants and is not recruiting new patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could show that MRI-guided biopsy is more accurate than standard biopsy for finding aggressive prostate cancer, potentially reducing unnecessary biopsies.
What could go wrong: This is a phase II trial with 288 participants, so results may not apply to all men. The study only includes African American and white men, limiting generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ELEVATED PSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ELEVATED PSA HEALTH STATUS UNKNOWN

Contacts and locations

Locations

Henry Ford Hospital Vattikuti Urology Institute

Detroit, Michigan, 48202, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of Maryland

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.